![James Lillie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
James Lillie served as the Chief Scientific Officer at OvaScience, Inc. in 2018.
Prior to that, he earned a doctorate degree from Harvard University and an undergraduate degree from Wesleyan University.
Precedenti posizioni note di James Lillie
Società | Posizione | Fine |
---|---|---|
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Direttore Tecnico/Scientifico/R&S | 07/12/2018 |
Formazione di James Lillie
Harvard University | Doctorate Degree |
Wesleyan University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- James Lillie